_256_384.jpg)
It has initiated investments for advanced medical equipment such as Cath Labs, neuro microscopes, bone marrow transplant units at select facilities
Investment of Rs 235 crores to add 411 beds in the next 18 months
EPS for the period at Rs. (7.57)
The hospital chain aggressively embarks on digitisation and is e-health ready
The acquisition will provide it with a foothold in the US $ 48 billion global animal health market
Idiopathic hypersomnia is a life-long condition, and the approval of Xywav will be instrumental in providing treatment for symptoms such as excessive sleepiness and difficulty waking, and in effectively managing this debilitating disorder
Domestic formulations business records 39 % growth while the international business revenue was largely flat as compared to Q1 FY21
EPS at Rs 32.19
Substantial reduction in losses
Income declines marginally
Subscribe To Our Newsletter & Stay Updated
